Greg Slabodkin

The additional investment at the drugmaker's Lebanon sites brings its total Indiana capital expansion commitments to more than $21 billion since 2020.

The company plans to exit operations in Idar-Oberstein, Marburg, and Tübingen in Germany by end of 2027, while Singapore operations are expected to conclude in Q1 2027.

The Japanese drugmaker was impacted by contract manufacturing organization obligations and an impairment charge related to its Odawara plant in Japan.

The CDMO is making progress with the production of different GMP batches, while a revenue growth contribution is expected to begin in the second half of 2026.

With Big Pharma's pledge of more than $500 billion to U.S. manufacturing and research, industrial production growth should improve over the next several years, says Newmark.

The company is actively supporting customer reshoring, which is first targeted in its CDMO business and then more broadly in bioproduction and analytical instruments.

The U.S. drug supply chain continues to be at risk due to America’s reliance on countries such as India and China, with 44% of shortage drugs relying on a

As a wholly owned subsidiary of Lupin Limited, the company is creating a customer-facing organization with an external service and trusted outsourcing partner mindset.

While pharmaceutical companies are investing in artificial intelligence, implementation remains the biggest challenge, according to data and analytics firm GlobalData.

With automation holding great potential for cell therapy production, the companies continue to raise capital in a race to scale infrastructure to GMP standards.